The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ADC Therapeutics, Inc. Common H0036K147 17,274 539,648 SH   SOLE   539,648 0 0
Autolus Therapeutics Limited Common 05280R100 355 39,740 SH   SOLE   39,740 0 0
Epizyme, Inc. Common 29428V104 25,320 2,331,534 SH   SOLE   2,331,534 0 0
G1 Therapeutics, Inc. Common 3621LQ109 25,614 1,423,794 SH   SOLE   1,423,794 0 0
Harpoon Therapeutics, Inc. Common 41358P106 64,753 3,898,422 SH   SOLE   3,898,422 0 0
iTeos Therapeutics, Inc. Common 46565G104 79,665 2,355,557 SH   SOLE   2,355,557 0 0
MEI Pharma, Inc. Common 552798202 26,764 10,137,859 SH   SOLE   10,137,859 0 0
Merus N.V. Common N5749R100 12,286 700,879 SH   SOLE   700,879 0 0
Oncorus, Inc. Common 68236R103 76,849 2,377,031 SH   SOLE   2,377,031 0 0
Repare Therapeutics, Inc. Common 760273102 81,920 2,388,337 SH   SOLE   2,388,337 0 0
TCR2 Therapeutics, Inc. Common 87808K106 104,264 3,370,982 SH   SOLE   3,370,982 0 0
Turning Point Therapeutics, Inc. Common 90041T108 37,613 308,686 SH   SOLE   308,686 0 0
YmAbs Therapeutics, Inc. Common 984241109 16,699 337,291 SH   SOLE   337,291 0 0